TrialNCT03796962Phase 2Active not recruiting
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
Study sponsor: Xenon Pharmaceuticals Inc. · XENE
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2021-09-02Actual
Enrollment · participants325Actual
Source updated2024-09-24Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.